DMS 454
1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
DMS-454 is a small cell carcinoma cell line isolated from the lung tissue of a patient at the time of autopsy. DMS-454 possesses dense-core vesicles and has the ability to release calcitonin. In the culture, DMS-454 presents as polygonal cells and adherent growth pattern, and can be grown in Waymouth’s MB 752/1 with 2mM Glutamine and 10% Fetal Bovine Serum (FBS) at 37 °C, 5% CO2. DMS-454 can be also cultured in RPMI1640 with 10% FBS. The confluent DMS-454 can be digested with 0.25% trypsin or trypsin/EDTA and a 1:3 split.
Why choose DMS 454 from AcceGen?
AcceGen provides robust support for DMS-454, ensuring its optimal viability. DMS-454 undergoes rigorous quality control procedures, including thorough assessments of sterility, viability, identity confirmation, and growth characteristics. These standardized measures ensure that DMS-454 is a trustworthy and advantageous resource for diverse scientific research endeavors.
| Product Code | DMS-454; DMS454 |
| Species | Human |
| Cat.No | ABC-TC0215 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Disease | Lung Small Cell Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Lung Cancer Cell Lines |
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
DMS-454 serves as a valuable research model for investigating the characteristics of small-cell lung cancer, a highly aggressive and metastatic form of cancer associated with poor patient prognoses, and developing novel therapies for these patients. For example, the utilization of DMS-454 provides an opportunity to identify the tumor markers specific to small cell lung cancer (SCLC) in the initial stage. Once these markers are identified, the next step involves assessing the effectiveness of antibodies targeting these markers within the context of CAR-T cell therapy. This approach aims to determine whether the antibodies can effectively engage the markers and initiate the desired immune response to eliminate cancer cells. By investigating the response of DMS-454 cells to the antibodies, valuable insights can be gained regarding their potential as therapeutic agents in CAR-T cell therapy for combating SCLC.
